Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited (TEVJF) Financial Performance & Income Statement Overview
Analyze Teva Pharmaceutical Industries Limited (TEVJF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Teva Pharmaceutical Industries Limited (TEVJF) Income Statement & Financial Overview
Review Teva Pharmaceutical Industries Limited TEVJF income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $3.89B | $4.23B | $4.33B | $4.16B |
| Cost of Revenue | $2.01B | $2.11B | $2.18B | $2.14B |
| Gross Profit | $1.88B | $2.12B | $2.15B | $2.02B |
| Gross Profit Ratio | $0.48 | $0.50 | $0.50 | $0.49 |
| R&D Expenses | $247.00M | $247.00M | $240.00M | $279.00M |
| SG&A Expenses | $919.00M | $952.00M | $924.00M | $939.00M |
| Operating Expenses | $1.36B | $2.15B | $2.20B | $2.03B |
| Total Costs & Expenses | $3.37B | $4.26B | $4.38B | $4.17B |
| Interest Income | $0.00 | -$48.00M | $0.00 | $0.00 |
| Interest Expense | $225.00M | $239.00M | $272.00M | $241.00M |
| Depreciation & Amortization | $244.00M | $269.00M | $259.00M | $259.00M |
| EBITDA | $763.00M | $261.00M | $207.00M | $254.00M |
| EBITDA Ratio | $0.20 | $0.06 | $0.05 | $0.06 |
| Operating Income | $519.00M | -$29.00M | -$51.00M | -$5.00M |
| Operating Income Ratio | $0.13 | -$0.007 | -$0.01 | -$0.001 |
| Other Income/Expenses (Net) | -$225.00M | -$218.00M | -$273.00M | -$240.00M |
| Income Before Tax | $294.00M | -$247.00M | -$324.00M | -$245.00M |
| Income Before Tax Ratio | $0.08 | -$0.06 | -$0.07 | -$0.06 |
| Income Tax Expense | $74.00M | $28.00M | $69.00M | $630.00M |
| Net Income | $214.00M | -$217.00M | -$437.00M | -$846.00M |
| Net Income Ratio | $0.05 | -$0.05 | -$0.10 | -$0.20 |
| EPS | $0.19 | -$0.19 | -$0.39 | -$0.75 |
| Diluted EPS | $0.18 | -$0.19 | -$0.39 | -$0.75 |
| Weighted Avg Shares Outstanding | $1.14B | $1.13B | $1.13B | $1.13B |
| Weighted Avg Shares Outstanding (Diluted) | $1.16B | $1.13B | $1.13B | $1.13B |
Over the last four quarters, Teva Pharmaceutical Industries Limited achieved steady financial progress, growing revenue from $4.16B in Q2 2024 to $3.89B in Q1 2025. Gross profit stayed firm with margins at 48% in Q1 2025 versus 49% in Q2 2024. Operating income totaled $519.00M in Q1 2025, maintaining a 13% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $763.00M. Net income rose to $214.00M, with EPS at $0.19. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan